Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.945
-0.005 (-0.53%)
Nov 21, 2024, 10:44 AM EST - Market open
Assertio Holdings Revenue
Assertio Holdings had revenue of $29.20M in the quarter ending September 30, 2024, a decrease of -18.03%. This brings the company's revenue in the last twelve months to $125.76M, down -25.77% year-over-year. In the year 2023, Assertio Holdings had annual revenue of $152.07M, down -2.67%.
Revenue (ttm)
$125.76M
Revenue Growth
-25.77%
P/S Ratio
0.72
Revenue / Employee
$2,372,887
Employees
53
Market Cap
90.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
Dec 31, 2019 | 229.53M | -26.54M | -10.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MultiPlan | 942.61M |
PetMed Express | 259.34M |
So-Young International | 206.62M |
EDAP TMS | 70.72M |
Generation Bio Co. | 18.58M |
Coya Therapeutics | 9.55M |
ASRT News
- 6 days ago - Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio - Business Wire
- 9 days ago - Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Assertio Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 9 days ago - Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio - Business Wire
- 10 days ago - Assertio Provides Response to Letter from Short-seller - GlobeNewsWire
- 13 days ago - Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud - Business Wire
- 5 weeks ago - Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 - GlobeNewsWire
- 6 weeks ago - Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire